{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-24-000029","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.450683+00:00","generated_at":"2026-06-03T09:03:48.428286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Labcorp Q1 adj EPS $3.68 vs $3.46 YoY; raises FY guidance midpoint","bullets":["Revenue $3.18B (+4.6% YoY); organic base business grew 6.7%.","Diluted EPS $2.69 vs $2.34; adjusted EPS $3.68 vs $3.46.","FY2024 adjusted EPS guidance raised to $14.45-$15.35 (prev $14.30-$15.40); FCF reaffirmed $1.0-$1.15B.","Acquisitions: selected Invitae assets, agreed to buy BioReference Health diagnostic assets, closed three deals including Baystate Health and Providence.","New holding company structure May 17; Labcorp Holdings Inc. replaces Labcorp as public entity; ticker LH unchanged; $0.72 dividend payable June 12."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-24-000029","json":"https://secwatch.observer/filing/0000920148-24-000029.json","markdown":"https://secwatch.observer/filing/0000920148-24-000029.md","text":"https://secwatch.observer/filing/0000920148-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014824000029/0000920148-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014824000029/lh-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:03:48.428286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5af5fbe37c7827d2f7bb3bac1bf5fb84253e6b5c","claim":"LABCORP HOLDINGS INC. reported first quarter ended March 31, 2024 results: revenue $3.18 billion, net income $228.3 million, EPS $2.69. Guidance raised.","evidence_excerpt":"Labcorp Announces 2024 First Quarter Results Updates Full-Year Guidance • Results from Continuing Operations for first quarter 2024 versus last year: ◦ Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% ◦ Diluted EPS: $2.69 versus $2.34 ◦ Adjusted EPS: $3.68 versus $3.46 • Full-Year 2024 Guidance: Raised midpoint and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014824000029/0000920148-24-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.18 billion"},{"label":"Net income","value":"$228.3 million"},{"label":"EPS","value":"$2.69"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}